gms | German Medical Science

67. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Koreanischen Gesellschaft für Neurochirurgie (KNS)

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

12. - 15. Juni 2016, Frankfurt am Main

Frequency of BRAF V600E mutations in 1,031 central nervous system neoplasms – a retrospective single center analysis

Meeting Abstract

  • Felix Behling - Abteilung für Neurochirurgie, Universitätsklinikum Tübingen, Germany
  • Alonso Barrantes-Freer - Institut für Neuropathologie, Universitätsmedizin Göttingen, Germany
  • Marcos Tatagiba - Abteilung für Neurochirurgie, Universitätsklinikum Tübingen, Germany
  • Christian Hartmann - Institut für Neuropathologie, Medizinische Hochschule Hannover, Germany
  • Christine Stadelmann - Institut für Neuropathologie, Universitätsmedizin Göttingen, Germany
  • Jens Schittenhelm - Abteilung für Neuropathologie, Universitätsklinium Tübingen, Germany

Deutsche Gesellschaft für Neurochirurgie. 67. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), 1. Joint Meeting mit der Koreanischen Gesellschaft für Neurochirurgie (KNS). Frankfurt am Main, 12.-15.06.2016. Düsseldorf: German Medical Science GMS Publishing House; 2016. DocMO.10.02

doi: 10.3205/16dgnc041, urn:nbn:de:0183-16dgnc0415

Veröffentlicht: 8. Juni 2016

© 2016 Behling et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objective: With the advent of deeper insights into the development and molecular identity of tumors, targeted therapies have become increasingly interesting and have shown efficacy in some tumor entities. The BRAF V600E mutation is one of those targets that can be approached e.g. with inhibitory antibodies. This has successfully been done in advanced malignant melanoma, a malignancy frequently harboring this mutation. The presence of the mutation as well as the clinical safety and efficacy of the antibody treatment has also been shown in other cancer diseases, which makes the BRAF V600E mutation a highly interesting oncological target.

Method: This study assesses the BRAF V600E mutation in 1,031 intracranial neoplasms using tissue microarrays and immunohistochemical staining with the VE1 antibody.

Results: Overall, only 53/1031 (0.5%) mutations were detected. It was found to be a very rare finding in neuroepithelial tumors (6/705, 1%) encompassing 2 astrocytomas WHO grade II (2/43, 5%), 1 gliosarcoma WHO grade IV (1/80, 1%) and 3 glioblastomas WHO IV (3/319, 1%). Interestingly, all three glioblastomas showed epithelioid histopathological features. Almost all mutated neuroepithelial tumors were exceptionally young (mean age of all 6 mutated cases 26.7 years). Within five rhabdoid meningiomas one was mutated (1/5, 20%) while the remaining analyzed meningiomas were of wildtype status (1/130, 1%). The majority of BRAF V600E mutations were found in cerebral metastases (46/139, 34%), among them a few that have not yet been described to show BRAF V600E mutations, such as parotid acinic cell carcinoma (1/1, 100%) and hepatocellular carcinoma (1/1, 100%).

Conclusions: We suggest routine screening for BRAF V600E mutations for epitheloid glioblastomas WHO grade IV and rhabdoid meningiomas WHO grade III. Also salivary gland neoplasms need further assessment regarding the role of the BRAF V600E mutation in tumorigenesis and clinical management. Immunohistochemical analysis using mutation-specific antibodies on tissue microarrays is a feasible, time-efficient and cost-efficient approach to high-throughput screening for specific mutations in large tumor series.